American Century Companies
ACRS icon

American Century Companies’s Aclaris Therapeutics ACRS Stock Holding History

American Century Companies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118,702
Closed -$445K – 2885
2026
Q1 		$445K Buy
118,702
+41,134
+53% +$139K ﹤0.01% 2548
2025
Q4 		$233K Buy
77,568
+45,780
+144% +$116K ﹤0.01% 2680
2025
Q3 		$60.4K Buy
+31,788
New +$55.4K ﹤0.01% 2765

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

American Century Companies's ACRS Position: Q2 2026 in Review

American Century Companies sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 118,702 shares — an estimated $445K sold.

American Century Companies first reported a position in ACRS in Q3 2025 and held it in 3 quarters. The position peaked at $445K in Q1 2026. 93 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • American Century Companies reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • American Century Companies sold 118,702 Aclaris Therapeutics shares in Q2 2026, an estimated $445K.
  • American Century Companies first reported a position in Aclaris Therapeutics in Q3 2025 and held it in 3 quarters.
  • American Century Companies's Aclaris Therapeutics position peaked at $445K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.